Ultragenyx announced on December 30, 2025 that it has finalized the rolling submission of its Biologics License Application to the FDA for DTX401, an AAV8 gene therapy targeting Glycogen Storage Disease Type Ia. The filing encompasses data from 52 treated patients with up to six years of follow-up, including randomized, double-blind, placebo-controlled Phase 3 GlucoGene results showing significant and clinically meaningful reductions in both quantity and frequency of daily cornstarch intake, maintenance of low hypoglycemia rates, improved euglycemia and fasting tolerance. Patient Global Impression of Change scores reflected meaningful quality-of-life gains. The therapy has received Rare Pediatric Disease, orphan drug, Fast Track and RMAT designations from the FDA, as well as orphan drug and PRIME designations from the European Medicines Agency.

Shares of Ultragenyx climbed 15.5% on above-average volume following completion of the rolling BLA submission. Trading volume reached roughly 11 million shares, compared with an average daily volume of 1.7 million. Despite this rally, the trend in earnings estimate revisions remains neutral to negative, with consensus analyst models projecting continued net losses through fiscal 2026 due to high R&D spend and limited approved product revenue. Investors should weigh near-term enthusiasm against the company’s cash burn rate, which totaled $350 million in R&D expenses during the first nine months of 2025.

Wells Fargo analyst Benjamin Burnett maintained an overweight rating on Ultragenyx but reduced his price target from $65 to $45, citing the recent failure of Phase 3 Orbit and Cosmic studies of setrusumab in osteogenesis imperfecta to meet primary endpoints. Burnett noted that secondary endpoints—including bone mineral density improvements—were achieved, and highlighted potential catalyst events such as FDA feedback on DTX401 and future data readouts. With Ultragenyx shares closing at $19.72 on December 29, 2025, the new target implies upside of more than 128%. The analyst emphasized that it is premature to abandon the company’s rare disease pipeline.

Ultragenyx’s pipeline beyond DTX401 includes multiple rare-disease programs supported by over $1 billion in cash and equivalents as of Q3 2025, providing runway into 2027. While net losses reached $275 million for the first nine months of 2025, the company expects to leverage its manufacturing partnerships and regulatory designations to accelerate submissions in Europe and Japan. Key upcoming milestones include FDA feedback on the DTX401 BLA, potential US approval in late 2026, and mid-2026 data updates from a Phase 1/2 study of UX003 in Pompe disease.